ASXL1 and leukemia: We also performed these analyses by considering CHIP as the occurrence of mutations also in SF3B1 and TP53 (in addition to TET2, DNMT3A, and ASXL1) or defined by the presence of mutations in any leukemia driver gene at a VAF of >2% (Supplementary Fig. S2).